Toll Free: 1-888-928-9744
Published: May, 2014 | Pages:
32 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
Dendreon Corporation - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'Dendreon Corporation - Product Pipeline Review - 2014', provides an overview of the Dendreon Corporation's pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Dendreon Corporation's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Dendreon Corporation including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Dendreon Corporation's human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Dendreon Corporation's pipeline products Reasons to buy - Evaluate Dendreon Corporation's strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Dendreon Corporation in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Dendreon Corporation's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Dendreon Corporation and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Dendreon Corporation - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Dendreon Corporation and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Dendreon Corporation Snapshot 5 Dendreon Corporation Overview 5 Key Information 5 Key Facts 5 Dendreon Corporation - Research and Development Overview 6 Key Therapeutic Areas 6 Dendreon Corporation - Pipeline Review 9 Pipeline Products by Stage of Development 9 Pipeline Products - Monotherapy 10 Dendreon Corporation - Pipeline Products Glance 11 Dendreon Corporation - Clinical Stage Pipeline Products 11 Phase II Products/Combination Treatment Modalities 11 Phase I Products/Combination Treatment Modalities 12 Dendreon Corporation - Early Stage Pipeline Products 13 Preclinical Products/Combination Treatment Modalities 13 Dendreon Corporation - Drug Profiles 14 lapuleucel-t 14 Product Description 14 Mechanism of Action 14 R&D Progress 14 D-3263 16 Product Description 16 Mechanism of Action 16 R&D Progress 16 Drug Targeting Carbonic Anhydrase IX 18 Product Description 18 Mechanism of Action 18 R&D Progress 18 Drug Targeting Carcinoembryonic Antigen 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 Dendreon Corporation - Pipeline Analysis 20 Dendreon Corporation - Pipeline Products by Target 20 Dendreon Corporation - Pipeline Products by Route of Administration 21 Dendreon Corporation - Pipeline Products by Molecule Type 22 Dendreon Corporation - Pipeline Products by Mechanism of Action 23 Dendreon Corporation - Recent Pipeline Updates 24 Dendreon Corporation - Dormant Projects 25 Dendreon Corporation - Discontinued Pipeline Products 26 Discontinued Pipeline Product Profiles 26 UK-279276 26 Dendreon Corporation - Company Statement 27 Dendreon Corporation - Locations And Subsidiaries 29 Head Office 29 Other Locations & Subsidiaries 29 Dendreon Corporation - Key Manufacturing Facilities 30 Appendix 31 Methodology 31 Coverage 31 Secondary Research 31 Primary Research 31 Expert Panel Validation 31 Contact Us 32 Disclaimer 32
List of Tables Dendreon Corporation, Key Information 5 Dendreon Corporation, Key Facts 5 Dendreon Corporation - Pipeline by Indication, 2014 8 Dendreon Corporation - Pipeline by Stage of Development, 2014 9 Dendreon Corporation - Monotherapy Products in Pipeline, 2014 10 Dendreon Corporation - Phase II, 2014 11 Dendreon Corporation - Phase I, 2014 12 Dendreon Corporation - Preclinical, 2014 13 Dendreon Corporation - Pipeline by Target, 2014 20 Dendreon Corporation - Pipeline by Route of Administration, 2014 21 Dendreon Corporation - Pipeline by Molecule Type, 2014 22 Dendreon Corporation - Pipeline Products by Mechanism of Action, 2014 23 Dendreon Corporation - Recent Pipeline Updates, 2014 24 Dendreon Corporation - Dormant Developmental Projects,2014 25 Dendreon Corporation - Discontinued Pipeline Products, 2014 26 Dendreon Corporation, Subsidiaries 29 Dendreon Corporation, Key Manufacturing Facilities 30
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.